Mesoblast (MESO) Return on Capital Employed (2015 - 2023)
Mesoblast (MESO) posted Return on Capital Employed of 7.56% for Q2 2023, down 57.15% sequentially from 4.81% in Q1 2023, and up 183.0% YoY from 2.67% in Q2 2022.
Mesoblast (MESO) Return on Capital Employed (2015 - 2023) Analysis & Trends
Mesoblast has reported Return on Capital Employed for 8 years, with the latest figure at 7.56% in Q2 2023.
- Quarterly Return on Capital Employed rose 183.0% year-over-year to 7.56% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 7.56% (up 183.0% YoY) and the FY2025 annual result came in at 9.94%, down 7.0% from the prior year.
- Return on Capital Employed retreated to 7.56% in Q2 2023 per MESO's latest filing, from 4.81% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 4.81% in Q1 2023 and troughed at 16.81% in Q2 2019.
- A 5-year average of 11.38% and a median of 11.99% in 2020 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2019 and 2022: Return on Capital Employed tumbled 656 bps in 2019, then surged 828 bps in 2022.
- Over 5 years, Return on Capital Employed stood at 13.18% in 2019, then rose by 9 bps to 12.06% in 2020, then fell by 15 bps to 13.84% in 2021, then jumped by 60 bps to 5.56% in 2022, then slumped by 36 bps to 7.56% in 2023.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 7.56%, 4.81%, and 5.56% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -7.56% |
| Mar 31, 2023 | -4.81% |
| Dec 31, 2022 | -5.56% |
| Sep 30, 2022 | -8.34% |
| Jun 30, 2022 | -9.39% |
| Mar 31, 2022 | -11.93% |
| Dec 31, 2021 | -13.84% |
| Sep 30, 2021 | -12.64% |
| Jun 30, 2021 | -12.66% |
| Mar 31, 2021 | -13.15% |
| Dec 31, 2020 | -12.06% |
| Sep 30, 2020 | -11.81% |
| Jun 30, 2020 | -9.44% |
| Mar 31, 2020 | -11.29% |
| Dec 31, 2019 | -13.18% |
| Sep 30, 2019 | -14.61% |
| Jun 30, 2019 | -16.81% |
| Mar 31, 2019 | -15.70% |
| Dec 31, 2018 | -15.44% |
| Sep 30, 2018 | -12.18% |